Potential of plants to produce recombinant protein products

다국어 초록 (Multilingual Abstract)

Plants have great potential as photosynthetic factories to produce pharmaceutically important and commercially valuable biomedicines and industrial proteins at low cost. The U.S. Food and Drug Administration (U.S. FDA) has approved the drug Elelyso (taliglucerase alfa) produced by carrot cells for treatment of type 1 Gaucher’s disease in 2012. The commercial potential of biomedicines produced by molecular farming has dramatically improved due to the success of an experimental drug called ZMapp, which has immunological activity in Ebola patients. A cocktail of three monoclonal antibodies was produced in tobacco (Nicotiana benthamiana) plants (Chen and Davis 2016). At present, very few drugs made by this technology have been approved by worldwide authorities such as the U.S. FDA. However, plants have been proposed as a novel paradigm for commercial production of proteins over the next decade. In recent years, leading researchers on molecular farming have given more priority to the area of animal-free therapeutic proteins such as parenteral and oral vaccines. Although plant-based platforms have considerable advantages over traditional systems such as bacterial and animal systems, there are several obstacles to commercial-scale production, especially with regards to improving the quality and quantity of plant-produced biologics and industrial materials. One of the biggest barriers to commercialization of this technology is the intense scrutiny of these new plant varieties by regulatory agencies and the public as well as the high costs associated with their regulatory approval.

참고문헌 (Reference)

1 이신우, "국내･외 GM식물의 개발 및 산업화 현황" 한국식물생명공학회 37 (37): 305-312, 2010

2 Gleba Y, "Viral vectors for the expression of proteins in plants" 18 : 134-141, 2007

3 Healy M, "U.S. seeks to speed up production of Ebola drug"

4 Qiang Chen, "The potential of plants as a system for the development and production of human biologics" F1000 ( Faculty of 1000 Ltd) 5 : 912-, 2016

5 Sack M, "The increasing value of plant-made proteins" 32 : 163-170, 2015

6 Topp E, "The case for plant-made veterinary immunotherapeutics" 34 : 597-604, 2016

7 Farran I, "Targeted expression of human serum albumin to potato tubers" 11 : 337-346, 2002

8 Yamanaka T, "TOM1, an Arabidopsis gene required for efficient multiplication of a tobamovirus, encodes a putative transmembrane protein" 97 : 10107-10112, 2000

9 Sparrow P, "Risk assessment and regulation of molecular farming - a comparison between Europe and US" 19 : 5513-5530, 2013

10 Wang YC, "Protein post-translational modifications and regulation of pluripotency in human stem cells" 24 : 143-160, 2014

11 Faye L, "Protein modifications in the plant secretory pathway: current status and practical implications in molecular pharming" 23 : 1770-1778, 2005

12 Shaaltiel Y, "Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system" 5 : 579-590, 2007

13 Rybicki EP, "Plant-made therapeutics: an emerging platform in South Africa" 30 : 449-459, 2012

14 Paul M, "Plant-made pharmaceuticals: Leading products and production platforms" 58 : 58-67, 2011

15 Shoji Y, "Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza" 7 : 41-50, 2011

16 Broz A, "Plant-based protein biomanufacturing" FEB15-, 2013

17 Hefferon KL, "Plant virus expression vectors set the stage as production platforms for biopharmaceutical proteins" 433 : 1-6, 2012

18 Tschofen M, "Plant molecular farming: Much more than medicines" 9 : 271-294, 2016

19 Gholamreza Salehi Jouzani, "Plant Molecular Farming: Future Prospects and Biosafety Challenges" OMICS Publishing Group 02 (02): e136-, 2013

20 Sylvester AW, "Patent No. U.S. 8993844 B1 Production of spider silk protein in corn"

21 Twyman RM, "Molecular farming in plants: host systems and expression technology" 21 : 570-578, 2003

22 Tusé D, "Manufacturing economics of plant-made biologics: case studies in therapeutic and industrial enzymes" 2014

23 Lyon K, "LeafBio announces conclusion of ZMapp™ clinical Trial. Therapy to treat ebola shows promise"

24 Malabadi RB, "Insulin plant, costus speciosus: ethnobotany and pharmacological updates" 3 : 151-161, 2016

25 Dugdale B, "In plant activation: an inducible, hyperexpression platform for recombinant protein production in plants" 25 : 2429-2443, 2013

26 Werner S, "High-level recombinant protein expression in transgenic plants by using a double-inducible viral vector" 108 : 14061-14066, 2011

27 Xu J, "Green factory: Plants as bioproduction platforms for recombinant proteins" 30 : 1171-1184, 2012

28 Cox KM, "Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor" 24 : 1591-1597, 2006

29 Hood EE, "From green plants to industrial enzymes" 30 : 279-283, 2002

30 Rosales-Mendoza S, "Food-grade organisms as vaccine biofactories and oral delivery vehicles" 34 : 124-136, 2016

31 Strasser R, "Controlled glycosylation of plant-produced recombinant proteins" 30 : 95-100, 2014

32 Paul MJ, "Commercialization of new biotechnology: a systematic review of 16 commercial case studies in a novel manufacturing sector" 13 : 1209-1920, 2015

33 Hood EE, "Commercial plantproduced recombinant protein products" Springer 15-25, 2014

34 Howard JA, "Commercial plantproduced recombinant protein products" Springer 1-11, 2014

35 Fischer R, "Commercial aspects of pharmaceutical protein production in plants" 19 : 5471-5477, 2013

36 MacDonald J, "Bringing plant-based veterinary vaccines to market: Managing regulatory and commercial hurdles" 33 : 1572-1581, 2015

37 Bakker H, "An antibody produced in tobacco expressing a hybrid b-1,4-galactosyltransferase is essentially devoid of plant carbohydrate epitopes" 103 : 7577-7582, 2006

38 Abiri R, "A critical review of the concept of transgenic plants: insights into pharmaceutical biotechnology and molecular farming" 18 : 21-42, 2015